Interview: Impact of COVID-19 Respiratory Illness on the Life Science Research Industry
With the gradual improvement of the COVID-19 situation in China in the past few days, along with a worsening situation across many regions, research on vaccines and related antiviral drugs has become a key issue for most people both inside and outside the life science research industry. However, the vaccine research and development (R&D) process is long and complex, especially considering the need for drugs to undergo time-consuming clinical trials. A large number of animal models are urgently needed to verify the efficacy and safety of new compounds before human trials. As an upstream industry for vaccine and drug R&D, what kind of effects will this pandemic have on the animal model field and associated life science research? We explore this issue in-depth with our Chief Scientific Officer, Dr. Marvin Ouyang. Dr. Marvin Ouyang Executive VP and Chief Scientific Officer, Cyagen US Inc Dr. Marvin Ouyang has been dedicated to the development of genetically engineered rodent